Previous 10 | Next 10 |
In my last Seeking Alpha article Athersys: Abundance of Opportunity , I gave an overview of the company, highlighted the late-stage programs under development, and offered my views on potential upcoming catalysts. The four months since the publishing of that article has seen an unfortunate ...
During the Q2 conference call , Athersys ( ATHX -8.1% ) provided an update on the status of its interactions with the Biomedical Advanced Research and Development Authority (BARDA) regarding a potential collaboration for its MultiStem as a therapy for patients experiencing acute...
Relief Therapeutics Holdings AG ( RLFTF ) is a Swiss Company that trades on the U.S. OTC Exchange in addition to its Swiss Stock Exchange Listing (RLF). Only a week ago, Relief Therapeutics was trading under .10 per share. It was the rediscovery of the properties of their drug RLF-100, a propr...
Fennec Pharmaceuticals (NASDAQ: FENC ) -31% on FDA rejection of Pedmark application. More news on: Fennec Pharmaceuticals Inc., Mesoblast Limited, Genesis Healthcare, Inc., Stocks on the move, , Read more ...
Image source: The Motley Fool. Athersys (NASDAQ: ATHX) Q2 2020 Earnings Call Aug 10, 2020 , 4:30 p.m. ET Operator Continue reading
Athersys, Inc. (ATHX) Q2 2020 Earnings Conference Call August 10, 2020 16:30 ET Company Participants Karen Hunady - Director of Corporate Communications and Investor Relations Ivor Macleod - Chief Financial Officer Gil Van Bokkelen - Chairman and Chief Executive Officer Confer...
Athersys (NASDAQ: ATHX ) : Q2 GAAP EPS of -$0.10 misses by $0.02 . Revenue of $84K (-97.9% Y/Y) vs. $1.06M consensus. Press Release More news on: Athersys, Inc., Earnings news and commentary, Healthcare stocks news,
Management to host conference call at 4:30 pm EDT today Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended June 30, 2020. Highlights of the second quarter of 2020 and recent events include: Initiated and advanced enrollment in the...
Shares of Athersys (NASDAQ: ATHX) rose over 29% today after Bank of America (BofA) Securities initiated coverage of the stem cell specialist with a buy rating and a $5 price target. Considering the stock remains under $3 per share even after today's jump, that implies significant upside if...
Athersys (NASDAQ: ATHX ) +9% as director Kenneth Traub disclosed stock purchase of 140,000 common stock on June 24. More news on: Athersys, Inc., Healthcare stocks news, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to ra...